AMR Bio contributes to US National Action Plan on combating antibiotic-resistant bacteria
UK privately-held AMR Bio has submitted written comments to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) ahead of the Council's 27th public meeting on June 16, 2026, contributing to the next iteration of the US National Action Plan on Combating Antibiotic-Resistant Bacteria (NAP-CARB).
The revival of PACCARB, which had been inactive since early 2025 and provides advice and recommendations to the Secretary of State and Human Services (HHS) in the USA, marks an important moment for the antimicrobial resistance (AMR) community. It signals renewed political commitment in the United States to tackling antibiotic resistance, bringing together industry, regulators and policymakers to address this growing challenge and accelerate access to new preventative and therapeutic solutions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze